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Radiation therapy has been used for treatment of
cancer for a long time [1]. In the thoracic region, it is
frequently used for management of Hodgkin and non-
Hodgkin lymphoma, lung cancer, esophageal cancer,
breast cancer, thymoma and other malignancies in the
thorax. The management of these malignancies has
undergone a major evolution during the last decades.
The majority of cancer patients now undergo some
form of combined radiation and chemotherapy. Ini-
tially the heart was thought to be relatively resistant to
radiation induced injury but the lately the existence of
radiation-induced heart disease has been established
[2]. Due to the success of radiation and chemotherapy
there is a growing cohort of survivors of cancers who
are at risk for the complications of radiation therapy of
the chest. These complications include arm edema,
pneumonitis, rib fractures, brachial plexopathy, sec-
ondary malignancies and cardiac toxicity. Unfortu-
nately, radiation can damage any component of the
heart. Pericarditis is a typical early complication, with
dense collagen and fibrin replacement of the adipose
tissue. Also coronary artery disease, cardiomyopathy,
valvular heart disease and conduction abnormalities
can occur years after radiation treatment [3]. The
histologic findings of radiation induced cardiotoxicity
are diffuse interstitial fibrosis and narrowing of arterial
vessels and capillaries [4]. There is a 50% reduction of
the ratio of capillaries to myocytes which in turn
results in myocardial cell death, ischemia and fibrosis.
Radiation also causes injury of the coronary artery
endothelial cells. It causes fibro-intimal hyperplasia,
which in turn leads to thrombus formation and lipid
deposition [5]. In some cases coronary spasm may
occur [6].
Radiation therapy ultimately can result in coronary
artery disease, fibrotic changes of cardiac leaflets or
valves, diastolic function and cardiac arrhythmias
[7–11]. Risk factors for radiation induced cardiac
toxicity are total radiation dose, radiation dose per
fraction, the volume of the heart exposed to radiation
and the concomitant administration of cardiotoxic
chemotherapy like anthracyclines and trastuzumab.
The paper of Gayed et al. in the present issue of the
International Journal of Cardiac Imaging addresses an
important clinical issue of patients who survived
esophageal and lung cancer [12]. The authors show
that one-third of the patients who received radiation
therapy with the heart in the radiation field developed
cardiac ischemia. Even more patients developed
cardiac complications and cardiac death. Although
cardiac ischemia was frequently seen, it was not
predictive for future cardiac complications. In a
multivariate analysis, a history or the presence of
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arrhythmias and a history of congestive heart failure
was associated with cardiac complications. Most of
the patients with cardiac ischemia did not have
anginal complaints. These findings are in agreement
with the study of Marks et al. [9], Heidenreich et al.
[13, 14] and the Dutch Late Effects Breast Cancer
Cohort, which studied the effects of cardiovascular
toxicity of radiation therapy in women with breast
cancer during a period of 10 years [15, 16] and the
SEER database [17]. The latter was a large study of
women, who survived breast cancer treated with
radiation therapy. It showed, that after irradiation the
risk of myocardial infarction, angina pectoris and
heart failure was increased compared to the women
without breast cancer.
The sample size in the study of Gayed was too
small and the follow-up time too limited to draw
conclusions if silent ischemia detected on myocardial
perfusion imaging was predictive for cardiovascular
events in this patient population. However, studies in
patients with coronary artery disease have shown
adverse outcome related to the episodes of asymp-
tomatic cardiac ischemia [18]. In a retrospective
review of patients treated with radiation therapy for
Hodgkin’s disease a relative risk for fatal myocardial
infarction of 41.5 over the age-matched general
population was shown. Death frequently occurred
long (3–22 years) after exposition to radiation [19].
Doctors who take care of patients with cancer who
have to be treated or have been treated with
radiotherapy of the chest should be aware of the
cardiac risks of irradiation. The clinical implication
of myocardial perfusion imaging in this group of
patients has to be established in large trials with a
long follow-up of at least 5–10 years.
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